Related Experiment Videos

Characterization of methadone receptor subtypes present in human brain and lung tissues

R Maneckjee1, J D Minna

  • 1Division of Surgical Oncology, Oregon Health Sciences University, Portland 97201, USA.

Life Sciences
|January 1, 1997
PubMed

Insights

The opioid methadone inhibits human lung cancer cell growth via unique binding sites. Identifying these distinct receptors may lead to targeted, less toxic cancer therapies.

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Background:

  • Opioids, primarily known for pain management, also influence tumor cell proliferation.
  • Methadone, a therapeutic opioid, demonstrates potential anti-cancer properties.
  • Non-conventional opioid binding sites are implicated in mediating methadone's effects.

Purpose of the Study:

  • To investigate the mechanism by which methadone inhibits human lung cancer cell growth.
  • To characterize the binding sites for methadone in different human tissues.
  • To explore the potential for developing targeted cancer therapies based on distinct methadone receptors.

Main Methods:

  • In vitro and in vivo studies of human lung cancer cell growth inhibition by methadone.
  • Pharmacological and biochemical characterization of methadone binding sites.
  • Comparative analysis of binding sites in human brain, normal lung, and lung cancer tissues.

Main Results:

  • Methadone significantly inhibits the growth of human lung cancer cells.
  • Evidence suggests the existence of multiple subtypes of high-affinity, non-conventional methadone binding sites.
  • Methadone binding sites in human brain and lung tissues are pharmacologically and biochemically distinct from each other and from known opioid receptors.

Conclusions:

  • Methadone exhibits anti-proliferative effects on human lung cancer cells through specific binding sites.
  • Distinct methadone receptor subtypes exist in different tissues, including cancer cells.
  • Targeting these distinct receptors could enable the development of more selective and less toxic anti-cancer drugs.

Related Concept Videos